Zetia Cost in Maine 2026: What You'll Actually Pay for Ezetimibe

What Ezetimibe Does and Why Maine Patients Use It

Ezetimibe works by blocking the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestine, reducing dietary and biliary cholesterol absorption by roughly 54% [1]. The FDA approved ezetimibe (Zetia) in October 2002 for adults with primary hyperlipidemia, either alone or combined with a statin [2]. Most Maine prescribers use it as a second-line add-on when statins alone fail to bring LDL-C to goal, or as a statin-sparing option for patients who cannot tolerate full statin doses.

The 2018 ACC/AHA cholesterol guideline names ezetimibe the preferred non-statin add-on for patients with atherosclerotic cardiovascular disease (ASCVD) whose LDL-C remains above 70 mg/dL on maximally tolerated statin therapy [3]. That recommendation rests largely on the IMPROVE-IT trial (N=18,144), which showed that simvastatin 40 mg plus ezetimibe 10 mg reduced major cardiovascular events by 6.4% relative to simvastatin alone over a median 6-year follow-up (32.7% vs. 34.7%; HR 0.936 to 95% CI 0.89, 0.99, P<0.001) [4]. The absolute risk reduction was modest, but the trial established that LDL-C lowering below 70 mg/dL with a non-statin agent translates into clinical benefit, not just a lab number improvement.

Ezetimibe lowers LDL-C by 18 to 25% as monotherapy and by an additional 21 to 27% on top of statin therapy, according to a Cochrane systematic review of 18 randomized trials [5]. For patients who cannot afford PCSK9 inhibitors (which can exceed $500/month even after rebates), ezetimibe offers meaningful LDL-C reduction at a fraction of the cost.

Ezetimibe Prices in Maine in 2026: Cash Pay vs. Brand

Generic ezetimibe costs approximately $15 per month at most Maine retail pharmacies in 2026 on a cash-pay basis. That figure represents a dramatic drop from the Merck brand list price of approximately $380 per month for Zetia.

Multiple generic manufacturers, including Teva, Mylan (Viatris), and Sandoz, entered the U.S. market after ezetimibe's primary patent expired in 2017. Competition drove prices down sharply. The FDA's generic drug approval database lists more than a dozen approved ezetimibe 10 mg tablet ANDAs as of 2024 [6]. That volume of competition keeps Maine pharmacy shelf prices near the $10, $20 range depending on chain, quantity, and whether a discount card is applied.

Without any coupon or assistance program, a GoodRx-type price at Walgreens, Hannaford Pharmacy, and Shaw's Pharmacy in Portland, Bangor, and Augusta typically runs $12, $18 for a 30-tablet supply of generic ezetimibe 10 mg. Paying the brand price for Zetia in 2026 makes sense only in very specific circumstances, such as a formulary that covers brand but not generic, or a documented bioequivalence concern raised by a prescriber.

One cost-relevant fact most patients miss: ezetimibe 10 mg is a single approved dose. You cannot save money by cutting a higher-dose tablet. The FDA label specifies 10 mg once daily as the only approved dose [2], so pill-splitting strategies that work for some other drugs do not apply here.

MaineCare (Maine Medicaid) Coverage for Ezetimibe

MaineCare covers ezetimibe with prior authorization (PA) for eligible members. The PA requirement means your prescriber must submit clinical documentation showing that diet modification and statin therapy have been tried and have not achieved LDL-C goals, or that statins are contraindicated.

The MaineCare Benefits Manual, Chapter II, Section 65 (Pharmacy Services) governs preferred drug list (PDL) placement for lipid-lowering agents [7]. Generic ezetimibe sits on the MaineCare PDL as a non-preferred drug, which triggers the PA step. Approved PAs are generally valid for 12 months before re-authorization is needed. A prescriber's office typically submits a PA using Maine DHHS's electronic PA portal, and decisions arrive within 72 hours for non-urgent requests.

For MaineCare members who receive ezetimibe after PA approval, the copay is $0, $3 depending on managed care plan enrollment and income level. Maine expanded Medicaid under the ACA in 2019; approximately 380,000 residents now qualify for MaineCare as of 2024 [8]. If your household income is at or below 138% of the federal poverty level, MaineCare enrollment is worth pursuing before paying cash for any long-term prescription.

If your PA is denied, Maine law provides an internal appeal right within the managed care organization and a subsequent external appeal through the Maine Bureau of Insurance [9]. Prescribers can also request a "clinically urgent" PA review completed within 24 hours when a delay would seriously jeopardize the patient's health.

Ezetimibe and Maine Private Insurance: What to Expect

Most commercial insurance plans sold on Maine's marketplace (CMS.gov) place generic ezetimibe on Tier 1 or Tier 2 of their drug formularies, resulting in copays of $5, $30 per 30-day supply [10]. Brand-name Zetia typically lands on Tier 3 or Tier 4, with copays ranging from $50 to $100 or coinsurance of 25 to 50% after the deductible.

Anthem Blue Cross Blue Shield Maine, Aetna, and Harvard Pilgrim (the three largest carrier groups offering individual plans in Maine as of 2025) all list generic ezetimibe as a covered drug. Formulary tier placement can change each January 1. Before assuming coverage, confirm the plan year's current formulary at the insurer's website or call the member services number on your insurance card.

Employer-sponsored plans follow the same general pattern. ERISA self-funded plans are not required to follow Maine state insurance mandates, but they nearly all cover generic ezetimibe because the cost to the plan is low. If your employer plan lists ezetimibe as non-covered, a formulary exception request citing IMPROVE-IT data and the 2018 ACC/AHA guideline [3] gives your prescriber a strong clinical basis for appeal.

Key point: step therapy requirements are common. Some Maine insurers require a documented trial of a preferred statin (usually atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) before approving ezetimibe. The required statin trial period is typically 60 to 90 days [10].

Compounded Ezetimibe in Maine: Is It Legal?

Compounded ezetimibe is legal in Maine when prepared by a state-licensed 503A pharmacy operating under a valid patient-specific prescription from a licensed prescriber. Federal law under 21 U.S.C. § 353a governs 503A compounding, and Maine's Board of Pharmacy enforces corresponding state rules [11].

The key legal requirement is that compounded ezetimibe must be prepared in response to a valid prescription for an identified individual patient. Bulk compounding and dispensing without a prescription is not permitted under 503A. Maine does not currently have a licensed 503B outsourcing facility producing ezetimibe, so all compounded ezetimibe in the state flows through 503A pharmacies.

Why would anyone compound ezetimibe when the generic tablet costs only $15/month? Some telehealth platforms bundle compounded ezetimibe into a broader cardiovascular or metabolic program at $0 additional cost, absorbing the pharmacy cost in the monthly subscription fee. Others formulate combination capsules, such as ezetimibe plus berberine or ezetimibe plus coenzyme Q10, that are not available as FDA-approved commercial products. These combination preparations have not been evaluated in clinical trials for bioequivalence or efficacy compared to the approved tablet, and the FDA has not approved any such combination [12].

Patients considering compounded ezetimibe should verify the pharmacy's Maine Board of Pharmacy license (searchable at maine.gov) and confirm the pharmacy complies with USP Chapter 795 standards for non-sterile compounding [13]. A pharmacist-verified certificate of analysis for each lot provides additional quality assurance.

Telehealth Prescribing of Ezetimibe in Maine

Maine law permits telehealth prescribing of ezetimibe. A licensed prescriber who has established a valid patient-provider relationship via telehealth (audio-video or, in some cases, asynchronous questionnaire under Maine's telehealth statute) may issue an ezetimibe prescription without an in-person visit [14].

Ezetimibe is not a controlled substance, so the DEA's in-person examination requirement for controlled substance telehealth prescribing does not apply. Maine's telehealth parity law (22 M.R.S. § 3173-C) requires MaineCare and most commercial insurers to reimburse telehealth visits at the same rate as in-person visits for covered services [14].

From a practical standpoint, a telehealth visit with a HealthRX-affiliated prescriber in Maine can produce an ezetimibe prescription the same day, sent electronically to any Maine pharmacy or to a 503A compounding pharmacy. Lab work, specifically a fasting lipid panel, is the only prerequisite most prescribers require before writing the initial prescription. Quest Diagnostics and LabCorp both have patient service centers in Portland, South Portland, Bangor, Auburn, and Augusta for patients who need baseline labs [15].

After the initial prescription, most Maine prescribers will manage ezetimibe refills via telehealth as long as a lipid panel is repeated at 6 to 12 weeks after starting therapy and annually thereafter, per ACC/AHA guideline monitoring recommendations [3].

Discount Programs and Savings Cards for Ezetimibe in Maine

Several programs can reduce the cost of ezetimibe further, even from the already low $15 generic cash price.

Merck Patient Assistance Program. Merck offers the Merck Helps program for patients who cannot afford brand-name Zetia and meet income eligibility criteria (generally below 400% of the federal poverty level with no adequate insurance) [16]. Approved patients may receive Zetia at no cost. Applications are processed through merck.com or by calling 1-800-727-5400.

Merck Zetia Savings Card. For commercially insured patients who pay out-of-pocket for brand Zetia, Merck's savings card reduces the copay to as low as $5 for eligible prescriptions. Maine residents on MaineCare or Medicare Part D are not eligible for manufacturer savings cards under federal anti-kickback rules [16].

GoodRx and NeedyMeds. Free discount cards from GoodRx, RxSaver, and NeedyMeds regularly show generic ezetimibe prices of $9, $18 at Maine pharmacies. These cards work at Hannaford Pharmacy, Rite Aid (Maine locations), CVS, Walmart Pharmacy, and independent pharmacies. They are not insurance and do not apply to insurance claims, but they often beat insurance Tier 2 copays for low-cost generics.

Maine Rx Plus. Maine's state pharmaceutical assistance program (Maine Rx Plus) is available to Maine residents who are uninsured or underinsured and do not qualify for MaineCare [17]. The program negotiates preferred pricing with manufacturers and can lower costs for eligible residents. Income eligibility is determined at the time of application.

340B Drug Pricing. Maine patients who receive care at federally qualified health centers (FQHCs), rural health clinics, or certain safety-net hospitals with 340B program status may access ezetimibe at 340B pricing, which is substantially below retail [18]. Maine FQHCs include Penobscot Community Health Care, Community Health and Counseling Services, and Caring Hands Dental. Ask your provider if the facility is a 340B-covered entity.

Clinical Monitoring: What Maine Prescribers Check

Starting ezetimibe requires a baseline fasting lipid panel. Repeat lipid testing at 6 to 8 weeks confirms LDL-C response. The target in patients with established ASCVD is LDL-C <70 mg/dL; for very high-risk patients, some guidelines recommend <55 mg/dL [3].

Liver enzyme elevation is rare with ezetimibe monotherapy. The FDA label reports hepatitis in fewer than 1% of patients in clinical trials [2]. Routine liver function test (LFT) monitoring is not required unless the patient is also taking a statin that carries its own LFT monitoring recommendation or has pre-existing hepatic disease.

Muscle symptoms are uncommon with ezetimibe alone but can compound myopathy risk when combined with high-dose statins. IMPROVE-IT reported myopathy in 0.2% of the ezetimibe-plus-simvastatin arm vs. 0.1% in the simvastatin-only arm over 6 years [4]. Patients should report new unexplained muscle pain or weakness promptly.

Drug interactions worth noting in Maine's prescribing context: cyclosporine significantly increases ezetimibe exposure (AUC increases approximately 3.4-fold) and bile acid sequestrants such as cholestyramine reduce ezetimibe absorption by about 55% when co-administered [2]. Spacing ezetimibe at least 2 hours before or 4 hours after a bile acid sequestrant mitigates this interaction.

Annual lipid monitoring thereafter, combined with a review of CV risk factors and statin dose optimization, aligns with the ACC/AHA monitoring framework [3]. The SHARP trial (N=9,270) also confirmed the LDL-lowering efficacy of ezetimibe-plus-simvastatin in patients with chronic kidney disease, a population common in Maine's aging rural demographic, with a 17% relative reduction in major atherosclerotic events (P<0.001) [19].

Ezetimibe vs. PCSK9 Inhibitors: The Maine Cost Comparison

When LDL-C targets are not met on maximally tolerated statin plus ezetimibe, PCSK9 inhibitors (alirocumab, evolocumab) are the next step per ACC/AHA guidance [3]. Their cost, however, is strikingly different. Evolocumab (Repatha) carries a list price near $6,000/year after Amgen's patient assistance program brings it to $0 for qualifying patients; commercial insurance copays still average $150, $450/year after manufacturer coupons [20].

Generic ezetimibe at $15/month equals $180/year, making it roughly 10, 30 times cheaper than out-of-pocket PCSK9 inhibitor costs for most insured Maine patients. The FOURIER trial (N=27,564) showed evolocumab reduced LDL-C by a median 59% and cut major CV events by 15% relative risk over 2.2 years [20]. That is a larger LDL-C and event reduction than ezetimibe, but the cost-effectiveness equation favors ezetimibe first for most patients.

The 2022 ACC Expert Consensus Decision Pathway explicitly recommends trialing ezetimibe before advancing to PCSK9 inhibitors in patients without recent ACS [3]. Maine insurers uniformly require documented ezetimibe use and failure before approving a PCSK9 inhibitor PA, making the sequential approach both clinically and financially rational.

How to Get Ezetimibe in Maine: Step-by-Step

Getting a prescription is straightforward. Schedule a telehealth visit with a licensed Maine prescriber, or visit your primary care provider or cardiologist. Bring or upload a recent lipid panel (within 3 months is ideal). The prescriber will confirm your CV risk category, review statin history, and write a 90-day supply with refills if ezetimibe is appropriate.

Send the prescription to any Maine retail pharmacy for generic ezetimibe at roughly $15/month, or request it be routed to a MaineCare-contracted pharmacy if you qualify. Apply a GoodRx or NeedyMeds coupon at checkout if you are paying cash. If you are enrolled in a telehealth platform that includes compounded ezetimibe, confirm the 503A pharmacy's Maine license before accepting delivery.

Request a 90-day supply rather than a 30-day supply. Most Maine pharmacies and mail-order pharmacies offer 90-day fills at a per-pill price equal to or slightly below the 30-day price, reducing the number of pharmacy trips and the total annual cost.

The 2018 ACC/AHA guideline states: "In patients with clinical ASCVD who are judged to be at very high risk and in whom LDL-C level remains 70 mg/dL or higher on maximally tolerated statin therapy, it is reasonable to add ezetimibe" [3]. That recommendation applies directly to the majority of Maine patients for whom ezetimibe is being considered.